GLP-1 Receptor Agonists in Type 2 Diabetes with End-Stage Renal Disease (ESRD)

Agent-Specific Recommendations

The American College of Cardiology recommends using liraglutide and semaglutide with caution in patients with ESRD, while exenatide and lixisenatide are contraindicated 1
Exenatide is contraindicated in severe renal impairment and ESRD due to renal elimination, as stated by the American College of Cardiology 1
Lixisenatide is contraindicated in severe renal impairment and ESRD, according to the American College of Cardiology 1
Liraglutide can be used with caution in ESRD, though limited data exists for this population, as noted by the American College of Cardiology and Kidney International 1, 2
Semaglutide can be used with caution in ESRD, with limited data available, as stated by the American College of Cardiology and Kidney International 1, 2
Dulaglutide can be used without dose adjustment in patients with eGFR >15 ml/min/1.73 m², according to Kidney International 2

Efficacy and Safety

GLP-1 receptor agonists retain glucose-lowering efficacy even in advanced CKD and ESRD, including dialysis patients, as confirmed by Kidney International 2
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines state that GLP-1 receptor agonists maintain antihyperglycemic effects across the full range of eGFR, including dialysis patients 2
GLP-1 receptor agonists do not cause hypoglycemia when used alone, as noted by Diabetes Care and Kidney International 2, 3
When combining with insulin or sulfonylureas, reduce doses of these agents by approximately 20% for insulin to prevent hypoglycemia, as recommended by the Journal of the American College of Cardiology and Kidney International 2, 4

Clinical Algorithm

The American Diabetes Association (ADA) and KDIGO recommend GLP-1 receptor agonists with proven cardiovascular benefit (liraglutide, semaglutide, dulaglutide) for patients with type 2 diabetes and CKD who do not meet glycemic targets with metformin and/or SGLT2 inhibitors, as stated by Kidney International 2
Metformin is contraindicated with eGFR <30 ml/min/1.73 m², and SGLT2 inhibitors have minimal glycemic effects at this level of kidney function, as noted by Kidney International 2
Reduce insulin dose by approximately 20% when initiating GLP-1 receptor agonist, as recommended by the Journal of the American College of Cardiology and Kidney International 2, 4

Special Considerations

In ESRD patients with obesity exceeding BMI limits for kidney transplant listing, GLP-1 receptor agonists can facilitate weight loss to meet transplant eligibility criteria, as stated by Kidney International 2
GLP-1 receptor agonists have not demonstrated significant effects on progression to ESRD or doubling of serum creatinine in clinical trials, as noted by Kidney International 2

Practical Pitfalls to Avoid

Do not use exenatide or lixisenatide in ESRD, as these are absolute contraindications, not just cautions, as stated by the American College of Cardiology 1
Do not forget to reduce insulin/sulfonylurea doses when initiating therapy to prevent hypoglycemia, as recommended by the Journal of the American College of Cardiology and Kidney International 2, 4
Do not combine with DPP-4 inhibitors, as this combination is not recommended, as stated by Kidney International 2
Do not ignore gastrointestinal symptoms, as severe nausea/vomiting can lead to dehydration and AKI in vulnerable ESRD patients, as noted by Kidney International 2
Do not overlook nutritional status, as weight loss may be detrimental in malnourished ESRD patients, as stated by Kidney International 2

GLP-1 Receptor Agonists in Kidney Disease Management

Current Evidence on GLP-1 RAs and Kidney Disease

The American College of Cardiology and Kidney International recommend GLP-1 receptor agonists for type 2 diabetes management and weight loss, not for kidney tumor treatment 5, 6
The FDA has issued a Black Box Warning regarding increased risk of thyroid C-cell tumors, and GLP-1 RAs are contraindicated in patients with personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 5, 7

GLP-1 RAs in Chronic Kidney Disease

GLP-1 RAs have demonstrated benefits in patients with chronic kidney disease (CKD) and type 2 diabetes, including reduction in albuminuria, slowing of eGFR decline, and reduction in major adverse cardiovascular events (MACE) 6, 8, 9, 10
The Kidney International guidelines recommend GLP-1 RAs with proven cardiovascular benefits, such as liraglutide, semaglutide, and dulaglutide, for patients with T2D and CKD who do not meet glycemic targets with metformin and/or SGLT2 inhibitors 6, 9, 11

Recommendations for Clinical Practice

The American Journal of Kidney Diseases recommends considering alternative glucose-lowering medications without known cancer risks for patients with both kidney tumors and type 2 diabetes requiring glucose management 5, 11
For patients with diabetes and CKD (without kidney tumors), GLP-1 RAs can be used in patients with eGFR as low as 15 ml/min/1.73 m², and even in dialysis patients, with careful monitoring and dose adjustments 6, 12

Important Considerations and Monitoring

The Kidney International guidelines recommend monitoring for common side effects, such as nausea, vomiting, and diarrhea, and being vigilant for signs of acute pancreatitis, a rare but serious potential adverse effect 6
The guidelines also recommend titrating doses slowly to minimize gastrointestinal side effects and reducing doses of insulin or insulin secretagogues to avoid hypoglycemia when used with GLP-1 RAs 6

Semaglutide Use in Chronic Kidney Disease

Efficacy and Benefits in CKD

Semaglutide can be used without dose adjustment in patients with any level of kidney function, including end-stage renal disease and dialysis, according to the American Diabetes Association 13, 14
The American College of Cardiology recommends confirming diagnosis of CKD, evaluating current glycemic control and weight management needs, and screening for contraindications before initiating semaglutide therapy 15, 16, 14

Clinical Decision Algorithm for Semaglutide in CKD

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest monitoring for gastrointestinal side effects, evaluating glycemic response and weight loss, and checking kidney function every 3-6 months while on semaglutide therapy 14, 16

Positioning in CKD Treatment Algorithm

The American Diabetes Association recommends semaglutide as a first-line agent alongside SGLT2 inhibitors for patients with type 2 diabetes and CKD, with a strength of evidence of high quality 15, 16
For patients with CKD and eGFR <45 mL/min/1.73m², the European Association for the Study of Diabetes suggests semaglutide as an excellent alternative first-line agent 15, 16

Best GLP-1 Receptor Agonist for CKD

Primary Recommendations by CKD Stage

The American College of Cardiology recommends starting with semaglutide, liraglutide, or dulaglutide for patients with type 2 diabetes and CKD, as these agents have the strongest evidence for cardiovascular and kidney protection, with semaglutide emerging as a fourth therapeutic pillar following the FLOW trial results, for patients with eGFR ≥30 ml/min/1.73 m² 17
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines suggest liraglutide showed greater MACE reduction in patients with eGFR <60 ml/min/1.73 m² compared to those with higher eGFR, making it particularly attractive in moderate CKD 17
For patients with eGFR 15-29 ml/min/1.73 m², dulaglutide is preferred as it can be used without dose adjustment down to eGFR >15 ml/min/1.73 m² and demonstrated significantly slower GFR decline compared to insulin glargine in patients with moderate-to-severe CKD 17

Kidney-Specific Benefits Demonstrated

Meta-analysis of 8 cardiovascular outcome trials showed GLP-1 RAs significantly reduced composite kidney disease outcomes, largely driven by albuminuria reduction, with a hazard ratio ranging from 0.35-0.87 17

Clinical Algorithm for Sequencing

The American Diabetes Association recommends adding GLP-1 RA if glycemic targets are not met or the patient is unable to take first-line agents, with semaglutide, liraglutide, or dulaglutide as options 17
Liraglutide is recommended if eGFR <60 ml/min/1.73 m² due to enhanced MACE benefit in this population 17
Dulaglutide is recommended if eGFR 15-29 ml/min/1.73 m² due to strongest data for GFR preservation in advanced CKD 17

Practical Considerations

The European Association for the Study of Diabetes suggests titrating GLP-1 RAs slowly to minimize gastrointestinal side effects, which occur in 15-20% of patients with moderate-to-severe CKD but usually abate over several weeks to months 17
Nausea, vomiting, and diarrhea are most common side effects, with severe symptoms leading to dehydration and acute kidney injury in vulnerable CKD patients 17
Heart rate typically increases by ~5 bpm but has not been associated with adverse cardiovascular events 17
A history of pancreatitis is a relative contraindication based on theoretical risk 17

GLP-1 Analogues in CKD: Use with Insulin for Insulin Resistance

Introduction to GLP-1 Analogues in CKD

The American Diabetes Association recommends that GLP-1 receptor agonists can be used in patients with chronic kidney disease (CKD) and can be safely combined with insulin, though insulin doses must be reduced by approximately 20% to prevent hypoglycemia 18, 19.

Use of GLP-1 RAs Across CKD Stages

GLP-1 receptor agonists retain full glucose-lowering potency across the entire range of eGFR, including patients with eGFR as low as 15 ml/min/1.73 m² and those on dialysis 18, 19.
Unlike SGLT2 inhibitors, which lose glycemic efficacy below eGFR 30 ml/min/1.73 m², GLP-1 RAs maintain their antihyperglycemic effects even in advanced CKD and end-stage renal disease 18, 20.
Meta-analyses demonstrate that cardiovascular risk reduction with GLP-1 RAs is at least as effective, if not more so, in patients with eGFR <60 ml/min/1.73 m² compared to those with higher eGFR 18.

Combination with Insulin: Practical Algorithm

The American College of Cardiology recommends reducing insulin dose by approximately 20% when starting GLP-1 RA therapy in patients with moderate-to-severe CKD 18.
For patients on basal insulin alone, reduce basal insulin by 20% 18.
For patients on basal-bolus regimens, reduce both components proportionally or consider eliminating bolus insulin first 18.

Mechanism: Addressing Insulin Resistance in CKD

The European Association for the Study of Diabetes states that GLP-1 RAs reduce insulin resistance indirectly through weight loss, which is particularly beneficial in CKD where insulin resistance is common 18.

Clinical Positioning in CKD Treatment Algorithm

For eGFR ≥30 ml/min/1.73 m², the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend first-line treatment with metformin + SGLT2 inhibitor 20.
If glycemic targets are not met, add GLP-1 RA (semaglutide, liraglutide, or dulaglutide preferred) 18, 19, 20.

Cardiovascular and Renal Benefits Beyond Glycemic Control

The American Heart Association notes that large cardiovascular outcome trials demonstrate that GLP-1 RAs with proven benefit (liraglutide, semaglutide, dulaglutide) reduce major adverse cardiovascular events (MACE) by 12-26% 18, 21.
Composite kidney outcomes are reduced, primarily driven by albuminuria reduction 18, 21.

Critical Safety Considerations and Pitfalls

The National Kidney Foundation advises that nausea, vomiting, and diarrhea occur in 15-20% of patients with moderate-to-severe CKD but usually abate over several weeks to months with slow dose titration 18.
Severe vomiting can lead to dehydration and acute kidney injury in vulnerable CKD patients 18.

Special Populationigli Population: Transplant Candidates

The International Society of Nephrology recommends that in ESRD patients with obesity exceeding BMI limits for kidney transplant listing, GLP-1 RAs can facilitate weight loss to meet transplant eligibility criteria 18.

GLP-1 Receptor Agonists in Chronic Kidney Disease

Agent-Specific Guidance

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend GLP-1 receptor agonists for patients with type 2 diabetes and chronic kidney disease (CKD), with specific agents like semaglutide, liraglutide, and dulaglutide being preferred due to their safety across all CKD stages, including dialysis 22
Semaglutide can be used without dose adjustment at any eGFR level, including dialysis patients, according to the Kidney International journal 22
Dulaglutide can be used without dose adjustment down to eGFR >15 ml/min/1.73 m², as stated in the Kidney International journal 22
Exenatide extended-release should only be used with eGFR ≥45 ml/min/1.73 m², as recommended in the Kidney International journal 22

Clinical Positioning

For patients with eGFR ≥30 ml/min/1.73 m², the American Diabetes Association recommends starting with metformin plus SGLT2 inhibitor as first-line therapy, and adding a long-acting GLP-1 RA if glycemic targets are not met, prioritizing agents with proven cardiovascular benefits 22
The Kidney International journal suggests that metformin is contraindicated for patients with eGFR 15-29 ml/min/1.73 m² 22

Practical Implementation

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines provide a strong (1B) recommendation for the use of GLP-1 RAs in patients with type 2 diabetes and CKD who have not achieved glycemic targets, as stated in the Kidney International journal 22
When initiating GLP-1 RA therapy, the Kidney International journal recommends confirming eGFR to select the appropriate agent, screening for contraindications, reducing insulin/sulfonylurea doses by 20% if applicable, starting at the lowest dose and titrating every 4-7 days, and monitoring for GI symptoms and renal function 22